TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Fortis Healthcare Ltd.

FORTIS on NSE · 19 Nov 2026

NIFTY 500 F&O

809.85 ▲ +2.05 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Filings

48 filings of FORTIS since December 2024; the newest 40 below.

board outcome 13, presentation 12, transcript 11, results 4, scheme 3, dividend 2

FiledTypeSubject
10 Nov 2026transcript
Acquisition, Capex, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q2 and H1 FY'27 earnings call, held on November 06, 2026, on its unaudited results for the quarter and half year ended September 30, 2026.

Management reported Q2 consolidated revenue of INR 2,735 crore, up 17.3% year on year, and Q2 operating EBITDA pre-ESOP of INR 663 crore, with margin of 24.2%.

H1 consolidated revenue was INR 5,280 crore, up 17.4%, and profit after tax excluding exceptional gains was INR 581 crore, up 3.8%; net debt was INR 2,188 crore, with net debt-to-EBITDA of 0.87x.

Management said it completed the acquisition of the 110-bedded Suguna Hospital in Bangalore and signed a long-term agreement for a 400-bedded greenfield hospital in Ashok Vihar, New Delhi.

Management said it is targeting about 600 bed additions in the current financial year, including the Suguna acquisition, and is evaluating M&A opportunities in Mumbai, Kolkata and Hyderabad.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2026presentation
Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its earnings presentation under Regulation 30 for the quarter and half year ended September 30, 2026 (Q2 FY27 and H1 FY27), dated November 5, 2026.

Q2 FY27 consolidated revenue was Rs 2,735 crores, with consolidated PAT (excluding exceptional items) of Rs 429 crores and consolidated PBT (excluding exceptional items) of Rs 317 crores at an 11.6% margin.

H1 FY27 consolidated revenue was Rs 5,280 crores, with consolidated PAT (excluding exceptional items) of Rs 783 crores and consolidated PBT (excluding exceptional items) of Rs 581 crores at an 11.0% margin.

Net debt was Rs 2,188 crores as on September 30, 2026, and net debt to annualized Q2 EBITDA was 0.87x, against 0.96x previously.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2026board outcome
Legal, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Fortis Healthcare Limited filed the outcome of its board meeting held on November 5, 2026, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a limited review report from the statutory auditor BSR & Co. LLP.

Standalone revenue from operations for the quarter ended September 30, 2026 was Rs 51,941 lacs, against Rs 45,581 lacs a year earlier; for the six months it was Rs 100,886 lacs versus Rs 88,884 lacs.

Standalone net profit from continuing operations for the quarter was Rs 12,991 lacs, against Rs 12,509 lacs a year earlier; for the six months it was Rs 17,769 lacs versus Rs 17,697 lacs.

The auditor's review report draws attention to the ongoing SFIO investigation into the Group, and to a Delhi High Court order dated August 31, 2026 appointing a forensic auditor to examine transactions with RHT Health Trust; the auditor's conclusion is not modified on these matters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Oct 2026acquisition
Acquisition
Fortis Healthcare Limited has informed the Exchange about Acquisition of entire business operations of Suguna Hospital, along with the underlying hospital land and building though its wholly- owned subsidiary - International Hospital Limite
AI summary

Fortis Healthcare Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations that its wholly-owned subsidiary International Hospital Limited signed and consummated, on October 28, 2026, the acquisition of the business and operations of Suguna Ramaiah Hospitals Private Limited and the land and building of Suguna Hospital in Rajajinagar, Bengaluru.

The transaction is a cash consideration deal with a cumulative transaction value of approximately INR 277 Crores, structured as a slump sale of business plus a sale deed for land and building.

Suguna Hospital is a 110-bedded facility commissioned in 2006, with potential to scale to about 150 beds; revenue from operations for the period ended March 31, 2026 was INR 49,79,86,452.

Management said the acquisition expands Fortis's presence in North West Bengaluru and takes its operational beds in the city to about 1,000, in line with its cluster-focused inorganic growth strategy.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Sep 2026transcript
Acquisition, Legal
Fortis Healthcare Limited has informed the Exchange about Transcript of Investors / Analysts meet held on Friday, September 4, 2026, on the recent developments
AI summary

Fortis Healthcare filed the transcript of an investor/analyst conference call held on September 4, 2026, under Regulation 30, following a Delhi High Court order directing a forensic audit.

Management (CEO Dr. Ashutosh Raghuvanshi, with IHH Group CFO Dilip Kadambi) said the order does not change the company's strategic or operational plans, including investment, capex, bed expansion and M&A.

Management said the audit covers the RHT transaction, IHH's investment in Fortis and the role of 17 banks; the court timeline is 4 weeks for the auditor's questionnaire, 2 weeks to respond, and 6 months for the report.

Management said it does not foresee any significant or material adverse results from the audit, and that IHH confirmed all its shares in Fortis were acquired as primary issuance, not from the open market.

Management said the company's legal teams are studying options and it will take action on their advice over the next couple of weeks, and will fully cooperate with the audit.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Aug 2026transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Management change, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q1 FY27 earnings call held on August 7, 2026, on the unaudited results for the quarter ended June 30, 2026.

Dr. Ashutosh Raghuvanshi (MD and CEO) said consolidated revenue was INR 2,545 crores, up 17.5% year-on-year, and consolidated operating EBITDA pre-ESOP was INR 568 crores at a 22.3% margin.

Management said hospital revenue grew 19% to INR 2,187 crores and diagnostic gross revenue grew 10.2% to INR 407 crores, with Agilus operating EBITDA margin at 23.9%.

Management said net debt was INR 2,233 crores, a net debt-to-EBITDA ratio of 1.01x as of June 30, 2026.

Vivek Goyal (CFO) said the company maintains its margin guidance, with a targeted 25% hospital EBITDA margin in about two years, while ESOP charges will weigh on near-term margins.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026presentation
Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its earnings presentation for the quarter ended June 30, 2026 (Q1 FY27), dated August 06, 2026.

Consolidated revenue was INR 2,545 crore, Operating EBITDA INR 568 crore (22.3% margin, excluding ESOP expenses of about INR 31 crore), PBT INR 354 crore and PAT INR 263 crore (both excluding exceptional items).

Net debt was INR 2,233 crore as on June 30, 2026, with net debt to annualised EBITDA at 1.01x versus 0.92x earlier.

Hospital business revenue grew 19% to INR 2,187 crore; hospital ARPOB was INR 2.71 crore per annum (up 2.6%) and occupancy was 68.7% versus 69.0%.

Diagnostics gross revenue was INR 407 crore, up 10.2%, with operating EBITDA margin of 23.9% excluding ESOP expenses.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026board outcome
Legal, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Fortis Healthcare filed the outcome of its board meeting held August 6, 2026.

The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a limited review report from statutory auditor B S R & Co. LLP.

The board appointed B S R & Co. LLP as Tax Auditors for financial year 2025-26, effective August 6, 2026.

The limited review report draws attention to an ongoing SFIO investigation into alleged improper transactions at the Group, for which a further provision was made in FY2020-21; management considers any further impact not expected to be material.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 Jul 2026board outcome
Management change
Fortis Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026 regarding re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director (designated as Managing Director and Chief Executive Offi
AI summary

Fortis Healthcare's board on July 8, 2026 recommended, subject to shareholder approval, the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and Chief Executive Officer for two years effective March 19, 2027, not liable to retire by rotation.

The current term of Dr. Raghuvanshi expires on March 18, 2027; the board cited his expertise and role in steering the company's growth.

Dr. Raghuvanshi, aged about 64, has over 38 years of healthcare experience, previously spent over 18 years at Narayana Health, and is not related to any other director.

The board meeting ran from 1:00 PM to 2:30 PM IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2026transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q4 and FY26 earnings conference call, held May 25, 2026, to discuss audited results for the quarter and year ended March 31, 2026.

Management said the Board recommended a dividend of INR1 per share (10% of face value), the fourth consecutive year, subject to shareholder approval.

FY26 consolidated revenue was INR9,128 crores (up 17.3%), consolidated operating EBITDA INR2,085 crores (22.8% margin) and consolidated profit after tax INR1,064 crores (up 31.5%), per management.

Q4 FY26 consolidated revenue was INR2,365 crores (up 17.8%) and profit after tax INR271 crores (up 44.2%); net debt stood at INR2,334 crores (net debt-to-EBITDA 1.09x).

Management reported FY26 capex of about INR700 crores, plans to add about 1,800 beds through brownfield expansion over four years, and said the hospital margin guidance of 25% by FY28 remains intact.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026presentation
Acquisition, Capex, Dividend / buy-back, Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its press release and earnings presentation for Q4 FY26 and FY26 (quarter and year ended March 31, 2026) under Regulation 30.

Q4 FY26 consolidated revenue was INR 2,365 Cr (up 17.8% YoY), operating EBITDA INR 531 Cr (up 22.2%, margin 22.5% vs 21.7%), and PAT INR 271 Cr (up 44.2%).

FY26 consolidated revenue was INR 9,128 Cr (up 17.3%), operating EBITDA INR 2,085 Cr (up 31.3%, margin 22.8% vs 20.4%), and PAT INR 1,064 Cr (up 31.5%).

The board recommended a dividend of INR 1 per share (10% of face value).

Net debt as of March 31, 2026 was INR 2,334 Cr, with net debt to EBITDA of 1.09x vs 0.93x a year earlier; management attributed the rise mainly to the acquisitions of People Tree Hospital (Bengaluru) and Shrimann Hospital (Jalandhar).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026dividend
Dividend / buy-back, Results
Fortis Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Re. 1 per equity share.
AI summary

Fortis Healthcare Limited's board approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from statutory auditor B S R & Co. LLP.

The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10 each) for FY 2025-26, subject to shareholder approval at the ensuing AGM.

The dividend will be paid or dispatched within 30 days of the AGM conclusion, if approved.

The board also appointed Jitender, Navneet & Co., Cost Accountants, as cost auditor for FY 2026-27, effective May 22, 2026, and approved a CSR policy.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026board outcome
Dividend / buy-back, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Fortis Healthcare Limited's board approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP.

The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10), subject to shareholder approval at the ensuing AGM, to be paid within 30 days of the AGM if approved.

The board appointed M/s Jitender, Navneet & Co., Cost Accountants, as Cost Auditor for FY 2026-27, effective May 22, 2026.

The board approved a Corporate Social Responsibility policy.

The board meeting commenced at 09:35 hours IST and concluded at 19:35 hours IST on May 22, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 Feb 2026transcript
Acquisition, Capex, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q3 FY26 earnings call held on February 16, 2026, covering the quarter and period ended December 31, 2025.

Management reported Q3 consolidated revenue of INR2,265 crores (up 17.5%) and operating EBITDA of INR505 crores (up 34.8%, margin 22.3% vs 19.4%); reported PAT was INR197 crores vs INR250 crores, hit by a INR55 crore one-off for New Labour Codes.

For 9 months FY26, consolidated revenue was INR6,763 crores (up 17.1%) and net debt was INR2,547 crores, with net debt to EBITDA of 1.24x as on December 31, 2025.

Management said in January 2026 it acquired the 125-bed People Tree Hospital in Bengaluru for INR430 crores, with plans to expand it to over 300 beds.

Management said Agilus Diagnostics posted Q3 gross revenue of INR371 crores (up 8.3%) and operating EBITDA margin of 23.1%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026presentation
Acquisition, Capex, Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its press release and earnings presentation for the quarter and nine months ended December 31, 2025 (Q3 FY26 and 9M FY26).

Consolidated revenue rose 17.5% YoY to INR 2,265 Cr in Q3 FY26; operating EBITDA rose 34.8% to INR 505 Cr, with margin at 22.3% vs 19.4% in Q3 FY25.

Profit after tax was INR 197 Cr in Q3 FY26, down 22.4% YoY, including an exceptional loss of INR 55.2 Cr from the one-time impact of New Labour Codes (net impact INR 45.9 Cr after an associate impairment reversal).

Net debt stood at INR 2,547 Cr as of December 31, 2025, with net debt to EBITDA of 1.24x vs 0.41x a year earlier, mainly due to funds raised for the Agilus Diagnostics PE stake acquisition and the Shrimann Hospital acquisition in Jalandhar.

Management (Dr Ashutosh Raghuvanshi, MD and CEO) said the hospital business grew healthily across key specialties, and that the diagnostics business's sustained recovery in revenue and EBITDA margin is encouraging and expected to progressively improve.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Legal, Management change, Results
Fortis Healthcare Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
AI summary

Fortis Healthcare filed the outcome of its board meeting held on February 13, 2026, which approved the unaudited standalone and consolidated financial results for the quarter and period ended December 31, 2025, along with the limited review report.

The board approved the formulation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (ESOP 2026), subject to shareholder and regulatory approvals, covering a pool of 1,50,99,163 options, each exercisable into one equity share of face value Rs. 10.

The board also approved a revision to the Related Party Transaction Policy.

The statutory auditor's limited review report draws attention to the ongoing SFIO investigation into the company and its subsidiaries regarding alleged improper transactions and non-compliances, and to legal proceedings and an EOW complaint against erstwhile promoters.

The board meeting commenced at 12:00 hours and concluded at 18:40 hours (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Legal, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Fortis Healthcare filed the outcome of its board meeting held February 13, 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review report from the statutory auditor.

The board approved formulation of the Fortis Healthcare Limited Employee Stock Option Scheme 2026 (ESOP 2026), subject to shareholder and regulatory approvals, with a pool of 1,50,99,163 options, each exercisable into one equity share of face value Rs. 10.

No options have been granted yet; the scheme is subject to shareholder approval via postal ballot.

The board also approved a revision to the Related Party Transaction Policy.

The auditor's review report draws attention to the ongoing SFIO investigation into the company and its subsidiaries relating to alleged improper transactions, which originated before the reconstituted board took control in FY2018; the company says further impact, if any, is not expected to be material.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Jan 2026scheme
Acquisition, Legal
Fortis Healthcare Limited has informed the Exchange about scheme of merger by absorption between wholly owned subsidiaries
AI summary

Fortis Healthcare filed a Regulation 30 disclosure on the composite scheme of merger by absorption of Fortis Emergency Services Ltd, Fortis Cancer Care Ltd, Fortis Health Management (East) Ltd and Birdie & Birdie Realtors Pvt Ltd into Fortis Hospitals Ltd, all wholly-owned subsidiaries.

The scheme was approved by NCLT New Delhi on January 5, 2026 and by NCLT Chandigarh on January 16, 2026; the appointed date is April 1, 2022.

The Chandigarh NCLT order was received by the company on January 15, 2026 at 07:20 PM.

The scheme becomes effective once certified copies of both NCLT orders are filed with the jurisdictional Registrar of Companies.

Fortis Hospitals Ltd had paid-up capital of INR 799.88 million and revenue from operations of INR 12,824.21 million for the year to March 31, 2025; the merged subsidiaries have nil turnover.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 Jan 2026presentationFortis Healthcare Limited has informed the Exchange about Presentation
AI summary

Fortis Healthcare filed an investor presentation titled "Non-Deal Roadshow / JP Morgan 2026 Healthcare Conference" for use at the 12th-15th January 2026 event in the USA, and said it will be posted on the company website.

The presentation covers the Indian healthcare market, the company's hospital and diagnostics networks, financial highlights, expansion plans and ESG initiatives.

As of 30 September 2025, the company cited 34 healthcare facilities, about 5,900 operational beds (including about 1,200 O&M beds), 7,600+ doctors and 9,200+ nurses.

Its diagnostics network has 400+ labs, 14,500+ pickup points and 4,300+ customer touch points; it reported 8.6 million patients and 20.7 million tests in H1FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Jan 2026credit rating
Rating
Fortis Healthcare Limited has informed the Exchange about Credit Rating
AI summary

Fortis Healthcare Limited filed under Regulation 30 and 51 of the SEBI Listing Regulations, disclosing that CRISIL Ratings reaffirmed its ratings on the company's bank facilities and non-convertible debentures.

Long-term rating reaffirmed at Crisil AA+/Stable and short-term rating at Crisil A1+; bank loan facilities rated Rs 425.98 crore and NCDs rated Rs 1,550 crore.

The rating action is dated January 05, 2026 (event time 5:31 PM), per the filing.

CRISIL's rationale cites expected revenue growth of 10-12% over fiscals 2026-2028, an operating (EBITDA) margin of 22-25% over the medium term, and gross debt of around Rs 3,400-3,500 crore by end of fiscal 2026.

CRISIL notes pending litigation (including the Supreme Court-directed Delhi High Court proceedings on RHT asset purchases) and regulatory risks as monitorable factors.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Nov 2025transcript
Acquisition, Capex, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q2 FY26 earnings call held November 12, 2025, covering the quarter and half year ended September 30, 2025.

Management (CEO Dr. Ashutosh Raghuvanshi) reported Q2 consolidated revenue of INR2,331 crores, up 17.3% year on year, and consolidated operating EBITDA of INR556 crores, a 23.9% margin versus 21.9% a year earlier.

Management reported H1 FY26 consolidated revenue of INR4,498 crores, up 16.9%, and net debt of INR2,219 crores, with net debt-to-EBITDA of 0.96x as on September 30, 2025.

Management said diagnostics (Agilus) Q2 revenue was INR399.6 crores, up 7.3%, with an operating EBITDA margin of 26.1%, and expects diagnostics margins of about 23-24% for the full year.

Management said it expects H2 hospital growth to remain similar to H1, with Q3 seasonally softer and Q4 typically better.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025presentation
Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its press release and earnings presentation for the quarter and half year ended September 30, 2025 (Q2 FY26).

Consolidated revenue was INR 2,331 Cr, up 17.3% YoY; operating EBITDA margin was 23.9% versus 21.9% in Q2 FY25; profit after tax was INR 329 Cr, up 70.3% YoY.

Hospital business revenue was INR 1,974 Cr, up 19.3% YoY, with operating EBITDA margin of 22.9%; diagnostics net revenue was INR 357 Cr, up 7.1% YoY.

Net debt was INR 2,219 Cr at September 30, 2025, with net debt to EBITDA of 0.96x, up from 0.16x a year earlier, mainly due to funds raised for the Agilus PE stake acquisition and the Shrimann Hospital acquisition.

Dr Ashutosh Raghuvanshi, MD and CEO, said the company has maintained healthy growth momentum and that diagnostics is seeing a buoyant recovery in revenue and EBITDA margin.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025results
Legal, Results
Fortis Healthcare Limited has informed regarding the Un-audited Financial Results for the Quarter and half Year ended September 30, 2025.
AI summary

Fortis Healthcare Limited's board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, on November 11, 2025, with a limited review report from BSR & Co. LLP.

Standalone revenue from operations for the quarter ended September 30, 2025 was Rs 45,581 lacs, against Rs 35,715 lacs a year earlier.

Standalone net profit for the quarter ended September 30, 2025 was Rs 12,509 lacs, against Rs 3,963 lacs in the year-earlier quarter.

Standalone net profit for the six months ended September 30, 2025 was Rs 17,697 lacs, against Rs 6,646 lacs a year earlier.

The auditor's report draws attention to the ongoing SFIO investigation into the Group and to a Supreme Court order of September 22, 2022 concerning transactions with RHT Health Trust; the auditor's conclusion is not modified on these matters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025board outcome
Legal, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Fortis Healthcare filed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, approved at a board meeting held November 11, 2025, with a limited review report from BSR & Co. LLP.

Standalone revenue from operations for the quarter ended September 30, 2025 was Rs 45,581 lacs, against Rs 35,715 lacs a year earlier; net profit for the quarter from continuing operations was Rs 12,509 lacs, against Rs 3,963 lacs a year earlier.

Standalone net profit for the six months ended September 30, 2025 was Rs 17,697 lacs, against Rs 6,646 lacs for the same period last year.

The auditor's report draws attention to the ongoing SFIO investigation into the Group and a Supreme Court order of September 22, 2022 concerning transactions with RHT Health Trust; the auditor's conclusion is not modified for these matters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Sep 2025credit rating
Rating
Fortis Healthcare Limited has informed the Exchange about Credit Rating
AI summary

Fortis Healthcare Limited filed intimation under Regulation 30 of SEBI LODR regarding a credit rating by CRISIL Ratings.

CRISIL upgraded the long-term bank facilities and non-convertible debentures to CRISIL AA+/Stable from CRISIL AA/Stable, and reaffirmed the short-term rating at CRISIL A1+.

Rated amounts: bank loan facilities Rs 425.98 crore; non-convertible debentures Rs 1,550 crore.

The event occurred on September 1, 2025 at 19:28 hours; the rating letter from CRISIL is enclosed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Sep 2025scheme
Acquisition, Legal
Fortis Healthcare Limited has informed the Exchange about effective date of Scheme of Arrangement
AI summary

Fortis Healthcare filed the certified copy of the NCLT Chandigarh Bench order for a composite scheme of arrangement with the Registrar of Companies via Form INC-28 on September 1, 2025 at 05:55 P.M. (IST).

The scheme involves International Hospital Limited, Fortis Hospitals Limited and Fortis Hospotel Limited, each a direct or indirect wholly-owned subsidiary of the company, and their shareholders and creditors.

The company states the scheme of arrangement came into effect from the date of filing, September 1, 2025.

This filing is a continuation of the earlier intimation dated July 31, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Aug 2025transcript
Acquisition, Capex, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q1 FY26 earnings call held on August 7, 2025, covering results for the quarter ended June 30, 2025.

Management (CEO Dr. Ashutosh Raghuvanshi) said consolidated revenue rose 16.6% to INR2,167 crores and operating EBITDA rose 43.2% to INR491 crores, a 22.6% margin versus 18.4% a year earlier; net debt was INR1,869 crores (0.92x net debt-to-EBITDA).

Management said the Hospital business revenue grew 18.6% to INR1,838 crores with ARPOB up 10.2% to INR2.65 crores per annum; Diagnostics (Agilus) gross revenue grew 7.4% to INR369 crores with operating EBITDA margin of 23%.

Management said it is on track to add about 900 beds this financial year, including the Jalandhar hospital acquired through a subsidiary, and reiterated its guidance of about 2% consolidated margin improvement for the year.

Agilus CEO Anand K guided to a full-year diagnostics operating margin of 22% to 23%; Fortis will receive a 3% of net revenue service fee under the Gleneagles India O&M agreement signed in July 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025presentation
Acquisition, Guidance, Management change, Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its press release and earnings presentation for the quarter ended June 30, 2025 (Q1 FY26), under Regulation 30.

Consolidated revenue was INR 2,167 Cr, up 16.6% YoY; operating EBITDA was INR 491 Cr with a 22.6% margin (vs 18.4% in Q1 FY25); PATMI was INR 260 Cr, up 56.8% YoY.

Hospital business revenue was INR 1,838 Cr, up 18.6% YoY, with a 22.1% operating EBITDA margin; diagnostic business net revenue was INR 329 Cr, up 6.3% YoY.

Net debt as of June 30, 2025 was INR 1,869 Cr, with net debt to EBITDA of 0.92x; the company said debt rose partly due to funds raised for the Agilus Diagnostics 31.5% PE stake acquisition and the Fortis brand acquisition.

Management (MD and CEO Dr Ashutosh Raghuvanshi) said the company had a healthy start to the year, cited the Gleneagles India O&M agreement (about 700 beds across five hospitals and a clinic), and expects diagnostics growth momentum to continue.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025presentation
Acquisition, Capex, Results
Fortis Healthcare Limited has informed the Exchange regarding a press release dated August 06, 2025, titled "press release and earnings presentation for the quarter ended on June 30, 2025.".
AI summary

Fortis Healthcare filed its press release and earnings presentation for the quarter ended June 30, 2025 (Q1 FY26), with unaudited consolidated revenue of INR 2,167 Cr, up 16.6% YoY, and operating EBITDA of INR 491 Cr, up 43.2% YoY, at a 22.6% margin (vs 18.4%).

Hospital business revenue was INR 1,838 Cr, up 18.6% YoY, with operating EBITDA margin of 22.1%; diagnostic business net revenue was INR 329 Cr, up 6.3% YoY, with operating EBITDA margin of 25.8%.

Profit after tax after minority interest and share in associates was INR 260 Cr vs INR 166 Cr in Q1 FY25; net debt was INR 1,869 Cr with net debt to EBITDA of 0.92x.

Management said the company signed an O&M services agreement with Gleneagles India covering about 700 beds across five hospitals and a clinic, and consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar (approx. 1,000 beds).

Dr Ashutosh Raghuvanshi, MD and CEO, said the company had a healthy start to the financial year and expects diagnostics growth momentum to continue.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025results
Legal, Results
Outcome of the Board Meeting for the consideration of Financial Results for June 30, 2025
AI summary

Fortis Healthcare filed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, approved by the Board at its meeting on August 06, 2025, along with the statutory auditor's limited review report.

The filing does not state the revenue, profit or other figures in the text provided.

The Board also appointed B S R & Co. LLP, Chartered Accountants, as Tax Auditors for Financial Year 2024-25, effective August 06, 2025.

The statutory auditor's limited review report draws attention to the ongoing SFIO investigation into the company and its subsidiaries and to a Supreme Court order of September 22, 2022 concerning transactions with RHT Health Trust; the auditor's conclusion is not modified on these matters.

The Board meeting commenced at 12:00 Noon IST and concluded at 8:25 PM IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2025board outcome
Legal, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Fortis Healthcare Limited filed the outcome of its board meeting held on August 06, 2025, including unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from the statutory auditor.

The board approved the appointment of B S R & Co. LLP, Chartered Accountants, as Tax Auditors for Financial Year 2024-25, effective August 06, 2025.

The statutory auditor's limited review report draws attention to the ongoing SFIO investigation into the Group's past transactions and to the Supreme Court's September 22, 2022 order concerning transactions with RHT Health Trust; the auditor's conclusion is not modified.

The board meeting commenced at 12:00 Noon IST and concluded at 8:25 PM IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2025scheme
Acquisition, Legal
Fortis Healthcare Limited has informed the Exchange about Scheme of Arrangement
AI summary

Fortis Healthcare filed a Regulation 30 disclosure on the composite scheme of arrangement between International Hospital Limited, Fortis Hospitals Limited and Fortis Hospotel Limited, all wholly-owned subsidiaries of the company.

The scheme was approved by NCLT New Delhi on May 9, 2025 and by NCLT Chandigarh on July 30, 2025; the appointed date is April 01, 2023.

The certified copy of the NCLT Chandigarh order is awaited; the scheme becomes effective once it is filed with the Registrar of Companies.

Annexure gives paid-up capital (March 31, 2025) of INR 3,396.31 million for IHL, INR 799.88 million (including CCPS) for FHsL and INR 5,611.70 million for FHTL.

Share exchange: IHL allots 191 equity shares of INR 100 each for every 237 CCPS of INR 10 each in FHsL; FHTL allots 713 equity shares of INR 10 each for every 329 equity shares of INR 10 each in FHsL.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
26 May 2025transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q4 FY25 and FY25 earnings call held on May 21, 2025, which discussed the audited results for the year ended March 31, 2025.

Management said FY25 consolidated revenue was INR 7,783 crores (up 12.9%), consolidated operating EBITDA was INR 1,588 crores (20.4% margin), and reported PAT before exceptional items was INR 899 crores (up 42.8%).

Management recommended a dividend of INR 1 per share (10% of face value), the third consecutive year, subject to shareholder approval.

Management said Q4 FY25 consolidated revenue was INR 2,007 crores (up 12.4%) with operating EBITDA of INR 435 crores (21.7% margin), and that FY25 capex was about INR 700 crores.

Management guided to hospital revenue growth of about 14-15% for FY26, with ARPOB growth of about 5-6% and the rest from volume, and to adding about 1,000 beds in the current year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2025presentation
Acquisition, Dividend / buy-back, Results
Fortis Healthcare Limited has informed the Exchange about Investor Presentation
AI summary

Fortis Healthcare filed its press release and earnings presentation for Q4 FY25 and FY25 (quarter and year ended March 31, 2025), dated May 20, 2025.

Q4 FY25 consolidated revenue rose 12.4% to INR 2,007 Cr; operating EBITDA rose 14.3% to INR 435 Cr, a 21.7% margin; PAT after minority interest and share in associates was INR 184 Cr.

FY25 consolidated revenue rose 12.9% to INR 7,783 Cr; operating EBITDA rose 25.3% to INR 1,588 Cr, a 20.4% margin; PAT after minority interest and share in associates was INR 774 Cr, EPS INR 10.26.

The board recommended a dividend of INR 1 per share (10% of face value), and the company acquired the perpetual rights to the 'Fortis' brand for INR 200 Cr.

Management (MD and CEO Dr Ashutosh Raghuvanshi) said the year showed "another year of healthy growth and margin improvement" and that the company continues to pursue inorganic growth opportunities; the Shrimann Superspecialty Hospital acquisition in Jalandhar is expected to be consummated shortly.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2025dividend
Dividend / buy-back, Legal, Results
Fortis Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of Rs. 1.00 per equity share.
AI summary

Fortis Healthcare filed the outcome of its board meeting held May 20, 2025, approving audited standalone and consolidated results for the quarter and year ended March 31, 2025, with an unmodified audit opinion from statutory auditors B S R & Co. LLP.

The board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10), for FY 2024-25, subject to shareholder approval at the ensuing AGM.

The board approved appointment of M/s Neelam Gupta & Associates as Secretarial Auditor for five years, April 1, 2025 to March 31, 2030, subject to shareholder approval.

The board appointed M/s Jitender, Navneet & Co. as Cost Auditor for FY 2025-26, effective May 20, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 May 2025board outcome
Dividend / buy-back, Results
Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Board of Fortis Healthcare approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with an unmodified audit opinion from statutory auditor BSR & Co. LLP.

The Board recommended a final dividend of ₹1 per equity share (10% of face value of ₹10), subject to shareholder approval at the ensuing AGM.

The Board approved appointment of M/s Neelam Gupta & Associates as Secretarial Auditor for five years from April 1, 2025 to March 31, 2030, subject to shareholder approval.

The Board appointed M/s Jitender, Navneet & Co., Cost Accountants as Cost Auditor for FY 2025-26, effective May 20, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2025transcript
Acquisition, Capex, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q3 FY25 earnings conference call held February 10, 2025, on the December 31, 2024 quarter results.

Management reported Q3 consolidated revenue of INR 1,928 crores (up 14.8% YoY), consolidated operating EBITDA of INR 375 crores (19.4% margin vs 16.9%) and PAT before exceptional items of INR 231 crores (up 82.2%).

Management said the company raised INR 1,550 crores via NCDs in December 2024 and acquired a 31.52% stake in Agilus, taking its holding to 89.2%; net debt was INR 644 crores (net debt to EBITDA 0.41x).

Management said the Richmond Road Hospital in Bangalore was divested in December 2024, the third facility divested after Malar and Vadapalani in Chennai.

Management expects Agilus to return to industry-level growth by the second quarter of next year and expects the Manesar facility to break even, at about INR 9 crores of monthly revenue, by Q1 next year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2025transcript
Acquisition, Capex, Guidance, Results
Fortis Healthcare Limited has informed the Exchange about Transcript
AI summary

Fortis Healthcare filed the transcript of its Q3 FY25 earnings call held on February 10, 2025, covering results for the quarter and period ended December 31, 2024.

Management said consolidated revenue for Q3 FY25 was INR 1,928 crores, up 14.8%, with consolidated operating EBITDA up 32% to INR 375 crores (19.4% margin) and profit after tax before exceptional items up 82.2% to INR 231 crores.

Management said hospital occupancy rose to 67% from 64% and ARPOB rose 9.9% to INR 2.45 crores per annum, with Dr. Raghuvanshi attributing most of the ARPOB growth to case mix.

Management said Agilus Diagnostics' Q3 FY25 revenue was INR 342.3 crores (up 3.5%) with operating EBITDA margin of 14.4%, and expects rebranding costs to taper off toward the end of the fiscal year.

Management said the Manesar facility is contributing about INR 5 crores per month of revenue with breakeven targeted around INR 9 crores per month by Q1 of next year, and that the Richmond Road Hospital in Bangalore was divested in December 2024.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Feb 2025transcript
Results
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, the audio recording of the investors / analysts meet held on February 10,2025 to discuss the Company s un-audited financial results fo
AI summary

Fortis Healthcare filed a notice under Regulation 30 of the SEBI LODR that the audio recording of its investors/analysts meet is available on the company website.

The meet was held on February 10, 2025, at 2.30 p.m., to discuss un-audited financial results for the quarter and period ended December 31, 2024.

The filing itself contains only the link to the recording; no management remarks or financial figures are included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Feb 2025presentation
Acquisition, Capex, Results
Fortis Healthcare Limited has informed the Exchange regarding a press release dated February 07, 2025, titled "Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please fi
AI summary

Fortis Healthcare filed its press release and earnings presentation for the quarter and nine months ended December 31, 2024 (Q3 FY25 and 9M FY25).

Q3 FY25 consolidated revenue rose 14.8% to INR 1,928 Cr; operating EBITDA rose 32.0% to INR 375 Cr, with a 19.4% margin (16.9% in Q3 FY24).

Hospital business revenue rose 16.8% to INR 1,623 Cr, with operating EBITDA of INR 325 Cr and a 20.0% margin.

The company's stake in Agilus Diagnostics rose from 57.68% to 89.20%, and the Richmond Road, Bangalore facility was divested in December 2024.

Net debt was INR 644 Cr as of December 31, 2024, with net debt to EBITDA of 0.41x.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in